Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Cyclopharm.
RELATED STOCKHEAD STORIES
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall but Dimerix up 150% on drug licensing deal
News
Market Highlights: ASX Futures down after a wild weekend in Washington, and 5 ASX small caps to watch today
News
CLOSING BELL: CBA makes bank from rising rates, then issues a warning about mortgage arrears
Health & Biotech
ASX Health Stocks: Cyclopharm confident after US FDA inspection; Anteris a step closer to FDA approval
Health & Biotech
These were the best ASX biotechs as Health Care sprang back to life in FY23
Experts
CRITERION: This ASX biotech is the sole dedicated player in a new $420 billion market
Health & Biotech
ASX Health Stocks: The US FDA will pay a visit to Cyclopharm’s facility in NSW
News
Market Highlights: Markets brace for more headwinds, and 5 ASX small caps to watch on Tuesday
Health & Biotech
ASX Health Stocks: Cyclopharm sends reply to FDA, the final step before potential approval
News
Market highlights and 5 ASX small caps to watch on Wednesday
Health & Biotech
ASX Health Stocks: FDA to expedite submission for Botanix’s sweaty armpits gel
Health & Biotech
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
Health & Biotech
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX
Health & Biotech
ASX Health Stocks: Clinical trials gather pace for Visioneering Tech, Anteris and other biotechs
Health & Biotech
ASX Health Stocks: IDT shoots 20pc on COVID-19 deal with government, ImpediMed granted US FDA Breakthrough
News
Market Highlights and 5 ASX Small Caps to watch on Monday
Health & Biotech
